TrOOPs: Tracking cost implications under IRA Part D reforms
As part of its many provisions, the Inflation Reduction Act (IRA) includes a dramatic...
As part of its many provisions, the Inflation Reduction Act (IRA) includes a dramatic...
Open claims and closed payer claims data are essential for understanding the status and activities...
FDA has made its expectations for RWE clearer and more structured through recent guidance and...
by: Alexandra Miller, MPH Human papillomavirus (HPV) is one of the most common sexually...
What real-world data reveals about the unique challenges of studying rare disease Primary biliary...
As the new year begins, many patients refocus on weight management and long-term health goals. At...
Early signals indicate continued declines in influenza vaccination uptake and shifts in the...
Identifying the gaps in today’s real-world data The 2025 IMPACCT Real-World Evidence Summit brought...
Recently, HealthVerity COO and co-founder Andrew Goldberg spoke at a timely webinar: Back to...
Why real-world data matters in epilepsy research Epilepsy affects millions of adults in the United...
We put the newest HealthVerity eXOs capabilities to the test on one of the most-watched questions in healthcare: who is starting GLP-1s, where they are and what happens next. Here is what the new features did and what the data revealed.